Rethinking drug design in the artificial intelligence era
| Autor: | Matthias Zentgraf, Elizabeth Krutoholow, Thomas S. Rush, Chris Luebkemann, Kimito Funatsu, Gisbert Schneider, Jeff Blaney, Alleyn T. Plowright, Norman Sieroka, John Edward Hill, Petra Schneider, Jennifer Listgarten, José S. Duca, Robert Alan Goodnow, Johanna M. Jansen, Jasmin Fisher, Matthias Kohler, W. Patrick Walters |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pharmacology business.industry media_common.quotation_subject General Medicine 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Drug development 030220 oncology & carcinogenesis Political science Drug Discovery Artificial intelligence business Skepticism media_common Grand Challenges |
| Zdroj: | Nature Reviews Drug Discovery. 19:353-364 |
| ISSN: | 1474-1784 1474-1776 |
| DOI: | 10.1038/s41573-019-0050-3 |
| Popis: | Artificial intelligence (AI) tools are increasingly being applied in drug discovery. While some protagonists point to vast opportunities potentially offered by such tools, others remain sceptical, waiting for a clear impact to be shown in drug discovery projects. The reality is probably somewhere in-between these extremes, yet it is clear that AI is providing new challenges not only for the scientists involved but also for the biopharma industry and its established processes for discovering and developing new medicines. This article presents the views of a diverse group of international experts on the 'grand challenges' in small-molecule drug discovery with AI and the approaches to address them. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink